It is very uncertain whether summary of findings: Comparison 2 ‐ deferasirox (DFX) changes SAEs Thalassaemia‐related SAEs compared with deferiprone (DFO) (very low certainty).

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
RR 0.95 [0.41, 2.17]
2 studies · 247 participants
Very low

Deferasirox vs deferiprone (DFO)

SAEs ‐ SCD‐related SAEs

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 195 participants
Very low

Deferasirox vs deferiprone (DFO)

All‐cause mortality

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
0.96 [0.06, 15.42]
2 studies · 240 participants
Very low

Hydroxyurea vs placebo

Reduction or prevention of kidney disease progression · people with sickle cell disease

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 142 participants
Very low

Angiotensin‐converting enzyme inhibitors vs vitamin C

Serious adverse events · children with sickle cell anaemia and microalbuminuria

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs vitamin C

Mortality due to any cause · children with sickle cell anaemia and microalbuminuria

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs vitamin C

Quality of life · children with sickle cell anaemia and microalbuminuria

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydroxyurea vs placebo

Serious adverse events · people with sickle cell disease

Hydroxyurea showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
RR 0.39 [0.13, 1.16]
1 study · 193 participants
Low

Hydroxyurea vs placebo

All‐cause mortality · people with sickle cell disease

1 finding from 1 review · compare the 2 reviews

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 193 participants
Low

Hydroxyurea vs placebo

Quality of life · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

Reduction or prevention of kidney disease progression · people with sickle cell disease

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low